We have been representing patients and their family in drug injury lawsuits for the past 15 years and this is our main practice area.
Drug injury legal compensation cases involve personal injury or wrongful death claims filed on behalf of people who, unfortunately, experienced a serious side effect, had an adverse drug reaction, or died from their use of a prescription medication.
Given our many years of experience handling these types of lawsuits we know drug injury cases deserve special attention.
Drug injury claims have a personal aspect which must be appreciated and respected by the attorney handling your case. At our law firm, we do not underestimate nor lose sight of the trust which is being placed in us by clients when they select us to represent them for their lawsuit against the responsible pharmaceutical company.
We will handle your drug injury case not only competently and professionally, but with genuine care and understanding. Any inquiries from our clients are responded to promptly, and telephone calls are always returned without delay.
If you, relatives, or friends need legal advice or legal representation for a personal injury lawsuit or a wrongful death lawsuit involving a drug side effect, the Law Offices of Thomas J. Lamb is here to help.
We encourage you to submit a Drug Injury Law Case Review — it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, or some other lawyer — about your case based on his many years of experience.
We handle these drug injury cases on a contingency fee basis, meaning that there is no payment for our legal services until we are successful in getting legal compensation for you.
While our office is in Wilmington, North Carolina, we have successfully handled drug injury lawsuits for people all over the United States.
It is important to note that we do not put our clients into large class actions. Rather we favor an individual lawsuit approach, which allows us to give personal attention to each of our clients, from start to finish.
Legal & Medical News: Featured Article
Another Blood-Clots Warning Label Change For YAZ Coming?
SUMMARY: In the past few years following an April 2012 YAZ label change there has emerged more medical evidence in support of the contention that birth control pills containing drospirenone (DRSP) are associated with higher rates of side effects caused by blood clots, such as deep vein thrombosis (DVT), pulmonary embolism (PE), strokes, and heart attacks.
As you may recall, the drug labels for Yasmin, YAZ, Safyral, and Beyaz were revised by Bayer and the FDA in April 2012 by adding information about the several different and conflicting (in terms of their conclusions) medical studies concerning the increased blood clot risks associated with drospirenone-containing birth control pills.
This “new” (vis-à-vis the April 2012 YAZ label change) medical evidence raises the possibility of there being another revised label for drospirenone birth control pills with a stronger and more clear, i.e., less ambivalent, warning about the increased risks of serious side effects involving blood clots.
There is a precedent for there being more than one such drug label change required by the FDA for contraceptive products like YAZ, Yasmin, Beyaz, and Safyral.
Back in 2008 we wrote this blog post, “Blood-Clot Warning On Ortho Evra Birth Control Patch Increased, Again, In January 2008″, which had as its sub-title: “Label For ‘The Patch’ No Longer Has Conflicting Information About Its Increased Risk Of Blood Clots” [emphasis added].
Given the mounting medical evidence that there is a real increased risk — not an arguable or theoretical risk — of developing a DVT, PE, stroke, or heart attack while using Beyaz, Safyral, Yasmin, or YAZ, one wonders whether DRSP birth control pills will follow the course of there being another blood-clots warning label change, as was done with the Ortho Evra patch.
- FDA May Require New Onglyza Drug Label For Warning About Heart Failure
- Federal Court Zofran MDL Motion; Generic Cases Filed In State Courts
- Invokana Lawsuits Filed While FDA Investigates Side Effects Reports
- Farxiga / Jardiance / Invokana: Ketoacidosis and Kidney Failure
- Bayer’s Numbers of YAZ / Yasmin Lawsuits and Settlements in April 2015
- Fosamax – Femur Fracture Lawsuits Update: California Verdict For Merck In April 2015 With Two More California Trials Scheduled For July 2015 And October 2015
- Invokana / Farxiga / Jardiance: New Medical Study Finds A History Of Diabetic Ketoacidosis Events Is Associated With Increased Risk of Death
- Multiple Myeloma Drug Pomalyst Associated With Side Effects Risks Of Cardiac Failure, Interstitial Lung Disease, And Hepatotoxicity